China's scientists unite in COVID-19 fight

19 February 2020
coronavirus_structure_large

In the battle against the novel coronavirus (COVID-19), Chinese Ministry of Science and Technology (MOST) has launched "Dealing With the Outbreak of COVID-19 Using Science and Technology," a program including four batches of 20 emergency projects until now.

Moreover, MOST is re-examining two major scientific and technological projects, including the "Creation of Important Innovative New Drugs" and the "Prevention and Treatment of Severe Contagions," and a series of national essential research and development plans. Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.

When it comes to drug screening, front-line staff from different research teams collaborated on the basis of existing researches, making great efforts to systematically and massively screen the drugs already on the market or already go into clinical trials. As a consequence, they discovered potentially effective anti-coronavirus drugs, such as chloroquine phosphate, remdesivir, and favipiravir. Furthermore, in recent days, researchers have urgently launched some clinical trials and the results show that the curative effect of drugs on patients is increasingly obvious.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical